Amneal Pharma rises; J.P.Morgan upgrades stock, raises PT

Amneal Pharmaceuticals

24/02/2025 09:34

** U.S. drug developer Amneal Pharmaceuticals  AMRX.O  rises
4.09% to $8.15 in premarket trading
    ** J.P.Morgan upgrades to "overweight" from "neutral"; lifts
PT from $9 to $12, ~42% upside to last close of $7.83
    ** Says co well-positioned for sustainable high single-digit
growth, driven by strong portfolio of complex generics and
biosimilars
    ** Expects AMRX to outperform peers significantly on
successful launch of Crexont, used to treat Parkinson's disease,
and AvKARE's (co's independent subsidiary) impressive growth
    ** Stock rated "buy" on avg; median PT is $11 - LSEG
    ** AMRX down 1.13% so far this year, as of Friday's close

 (Reporting by Rashika Singh in Bengaluru)
 ((rashika.singh@thomsonreuters.com))